1. Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model [Journal Article; Research Support, NIH, Extramural; Research Support, US Gov’t, Non-PHS]. 2022;62(2):412–22.
2. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron Variant. N Engl J Med [Letter; Research Support, Non-US Gov’t]. 2022;386(10):995–8.
3. Rockett R, Basile K, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, et al. Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. N Engl J Med [Letter]. 2022;386(15):1477–9.
4. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. LANCET INFECT DIS [Journal Article; Review]. 2022;22(11):e311–26.
5. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. [Journal Article; Research Support, Non-US Gov’t]. 2022;603(7902):700–5.